Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheuma
- PDF / 715,738 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 138 Views
ORIGINAL RESEARCH
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study Pascal Hilliquin . Thomas Barnetche . Athan Baillet . Rene´-Marc Flipo . Eric Lespessailles . Christian Roux . Patrice Fardellone . Anika Gilbert-Marceau . Isabelle Idier . Arnaud Constantin . Emilie Shipley . Guy Baudens . Alain Saraux Received: August 27, 2020 / Accepted: November 3, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients with moderate to severe active rheumatoid arthritis (RA).
P. Hilliquin (&) Rheumatology Department, C.H. Sud Francilien, Corbeil-Essonnes, France e-mail: [email protected] T. Barnetche Rheumatology Department, University Hospital of Bordeaux, FHU ACRONIM, Bordeaux, France A. Baillet Rheumatology Department, University Hospital of Grenoble, Grenoble, France R.-M. Flipo Rheumatology Department, University Hospital of Lille, Lille, France E. Lespessailles Rheumatology Department, General Hospital of Orle´ans, Orle´ans, France C. Roux Rheumatology Department, University Hospital of Nice, Nice, France P. Fardellone Rheumatology Department, University Hospital of Amiens, Amiens, France
Methods: This non-interventional, prospective, multicenter study (NCT02608112) was conducted in patients with RA initiating TCZ-SC treatment, with an 18-month follow-up. RR was estimated at month 12 in the overall population and baseline subgroups (combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD) or not, age, body mass index, methotrexate dose), using the Kaplan–Meier method. Patient compliance to A. Gilbert-Marceau Medical Data Department, Roche SAS, BoulogneBillancourt, France I. Idier Medical Affairs, Chugai Pharma France, Paris La De´fense, Puteaux, France A. Constantin Rheumatology Department, University Hospital of Toulouse, Toulouse, France E. Shipley Rheumatology Department, General Hospital of Dax, Dax, France G. Baudens Rheumatology, Private Practice, Valenciennes, France A. Saraux Rheumatology Department, CHU de Brest, Univ Brest, Inserm UMR1227, Lymphocytes B et Autoimmunite´, Brest, France
Rheumatol Ther
TCZ-SC was described using the 5-item Compliance Questionnaire for Rheumatology (CQR5). Results: At inclusion 75% of the 285 analyzed patients were women, mean RA duration was 9 ± 9 years, previous RA treatments included biological agents (63%) and/or csDMARDs (94%), mean Disease Activity Score 28 jointsErythrocyte Sedimentation Rate (DAS28-ESR) was 4.8 ± 1.2. TCZ-SC RR at month 12 was estimated to be 64% (95% CI 58%–69%) with no statistical differences between subgroups. Clinical results improved with TCZ-SC; the proportion of patients treated with combined glucocorticoids decreased from 49% to 22% at month 12. At each follow-up time, at least 80% of patients were high adhe
Data Loading...
